secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2026-05-21T10:04:26+00:00
Accession:  0001493152-26-024707
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR
--------------------------------------------------------------------------------

- All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
- CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.
- All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.
- Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.
- Next NEXICART-2 data update expected late September 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/0001493152-26-024707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer